Latest Headlines

31. Phanes Therapeutics To Present At BioFuture™ 2022 11/4/2022

    Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it is presenting at BioFuture™ 2022, which will take place at Lotte New York Palace, New York city, and providing an on-demand company presentation.

32. Exelixis And Catalent Enter Into New License Agreement For Three Antibody-Drug Conjugate Programs With The Potential To Accelerate Exelixis’ Biologics Pipeline 11/3/2022

    Exelixis, Inc. and Catalent, Inc. today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.

33. Intas Enters Into An Exclusive License Agreement With Syna To Commercialize LB-0702 In Global Markets 11/3/2022

    Syna Therapeutics, a joint venture of Reig Jofre and Leanbio, has signed a global rights licensing deal with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702.

34. iBio Accelerates Transformation To AI-Powered Biotech 11/3/2022

    iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company.

35. Emalex Biosciences Announces $250M Financing Round To Advance Investigational New Drug For Tourette Syndrome 11/3/2022

    Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.

36. Creative Medical Technology Holdings Announces FDA Clearance Of Investigational New Drug (IND) Application For AlloStem™, A Novel Cell Therapy For The Treatment Of Type 1 Diabetes 11/3/2022

    Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™.

37. Omega Therapeutics Receives Orphan Drug Designation For OTX-2002 For The Treatment Of Hepatocellular Carcinoma 11/2/2022

    Omega Therapeutics, Inc. ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company's first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).

38. Ascletis Announces U.S. IND Filing Of Oral 3CLpro Inhibitor ASC11 For COVID-19 11/1/2022

    Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been filed to the U.S. Food and Drug Administration (FDA) after the Pre-IND consultation.

39. Verge Genomics Initiates First-In-Human Dosing In Phase 1 Trial Of VRG50635, A Novel Therapeutic For Amyotrophic Lateral Sclerosis 10/31/2022

    Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that the first subject has been dosed in a Phase 1 clinical trial of VRG50635.

40. Ubiquigent Obtains Exclusive License For UbiSite Technology To Strengthen Its Specialist Drug Discovery Services 10/31/2022

    Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite technology.